Clinical-stage biotechnology company developing CRISPR-based precision genome-editing medicines for genetic diseases
Clinical-stage biotechnology company developing CRISPR-based precision genome-editing medicines for genetic diseases. Its in vivo therapies aim to provide affordable, one-time treatments by editing disease-associated genes in targeted organs and tissues. Core capabilities include novel Cas nuclease discovery and delivery using lipid nanoparticles and engineered protein delivery vehicles.